13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001631134
Total reported value
$1.9B
$1.9B
62 檔
28.7%
According to the latest 13F quarterly dataset, Sofinnova Investments, Inc. managed an equity portfolio of $1.9B at the end of Q1 2025, spanning 62 distinct U.S. exchange-listed positions.
In Q1 2025, Sofinnova Investments, Inc. displayed an active expansion posture, initiating 62 new positions and adding to 0 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NTRA | Natera Inc | Stock-Healthcare | 14.32% | +9.98% | — | |
| 2 | SYK | Stryker CORP | Stock-Healthcare | 7.26% | -0.56% | EXIT | |
| 3 | QQQ | Invesco Qqq Trust Series 1 | ETF-Tech | 5.36% | -3.29% | EXIT | |
| 4 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 4.73% | -0.02% | EXIT | |
| 5 | IWM | Ishares Russell 2000 ETF | ETF-Small Cap | 4.56% | -5.66% | EXIT | |
| 6 | VERA | Vera Therapeutics Inc | Stock-Other | 4.38% | +1.93% | — | |
| 7 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 4.14% | +0.25% | +1.16% | |
| 8 | MDT | Medtronic plc | Stock-Healthcare | 3.30% | — | — | |
| 9 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 3.11% | — | +59.94% | |
| 10 | GILD | Gilead Sciences Inc | Stock-Healthcare | 3.07% | +2.24% | NEW | |
| 11 | LLY | Eli Lilly & Co | Stock-Healthcare | 2.85% | — | +267.59% | |
| 12 | IDYA | Ideaya Biosciences Inc | Stock-Other | 2.81% | +0.35% | +145.27% | |
| 13 | AVBP | Arrivent Biopharma Inc | Stock-Other | 2.05% | +1.56% | — | |
| 14 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 1.93% | — | — | |
| 15 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.83% | — | +245.45% | |
| 16 | DXCM | Dexcom Inc | Stock-Healthcare | 1.77% | -0.94% | EXIT | |
| 17 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.66% | -1.15% | EXIT | |
| 18 | REPL | Replimune Group Inc | Stock-Other | 1.58% | -0.30% | EXIT | |
| 19 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.55% | +0.85% | +12.43% | |
| 20 | INSM | Insmed Inc | Stock-Healthcare | 1.52% | -1.28% | +18.72% | |
| 21 | 2655787D | Blueprint Medicines CORP | Stock-Other | 1.51% | — | — | |
| 22 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 1.48% | -1.97% | — | |
| 23 | INCY | Incyte CORP | Stock-Healthcare | 1.41% | — | -31.75% | |
| 24 | ANAB | Anaptysbio Inc | Stock-Other | 1.41% | +1.20% | +772.68% | |
| 25 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 1.37% | — | -23.59% | |
| 26 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.35% | — | — | |
| 27 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.34% | -0.62% | -70.37% | |
| 28 | RAPP | Rapport Therapeutics Inc | Stock-Other | 1.31% | +1.84% | — | |
| 29 | SUPN | Supernus Pharmaceuticals Inc | Stock-Healthcare | 1.11% | +0.62% | — | |
| 30 | SVRA | Savara Inc | Stock-Other | 0.99% | +0.04% | +0.19% | |
| 31 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.95% | +0.34% | +64.51% | |
| 32 | COGT | Cogent Biosciences Inc | Stock-Other | 0.85% | -1.02% | +165.09% | |
| 33 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.84% | -0.50% | EXIT | |
| 34 | DHR | Danaher CORP | Stock-Healthcare | 0.78% | — | +486.06% | |
| 35 | PEN | Penumbra Inc | Stock-Healthcare | 0.75% | — | — | |
| 36 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.73% | — | +2655.32% | |
| 37 | INBX | Inhibrx Biosciences Inc | Stock-Other | 0.64% | +0.44% | +32.38% | |
| 38 | YMABUSD | Y-mabs Therapeutics Inc | Stock-Other | 0.63% | — | — | |
| 39 | ✓ | Stock-Other | 0.62% | — | — | ||
| 40 | PHVS | Pharvaris N.V. | Stock-Other | 0.61% | +0.70% | +5.83% | |
| 41 | BIOA | Bioage Labs Inc | Stock-Other | 0.57% | +1.39% | — | |
| 42 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 0.54% | -0.07% | EXIT | |
| 43 | RCUS | Arcus Biosciences Inc | Stock-Other | 0.53% | +0.75% | — | |
| 44 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.49% | +0.77% | -33.09% | |
| 45 | ✓ | Immatics NV | Stock-Other | 0.46% | +0.56% | +352.88% | |
| 46 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.39% | -0.67% | — | |
| 47 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 0.39% | +0.82% | NEW | |
| 48 | QURE | uniQure N.V. | Stock-Other | 0.38% | — | — | |
| 49 | IMNM | Immunome Inc | Stock-Other | 0.35% | +0.47% | +5.60% | |
| 50 | KURA | Kura Oncology Inc | Stock-Other | 0.34% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NTRA | Natera Inc | — | NEW | New buy |
| 2 | SYK | Stryker CORP | — | NEW | New buy |
| 3 | QQQ | Invesco Qqq Trust Series 1 | — | NEW | New buy |
| 4 | SLNOEUR | Soleno Therapeutics Inc | — | NEW | New buy |
| 5 | IWM | Ishares Russell 2000 ETF | — | NEW | New buy |
| 6 | VERA | Vera Therapeutics Inc | — | NEW | New buy |
| 7 | JAZZ | Jazz Pharmaceuticals plc | — | NEW | New buy |
| 8 | MDT | Medtronic plc | — | NEW | New buy |
| 9 | ALNY | Alnylam Pharmaceuticals Inc | — | NEW | New buy |
| 10 | GILD | Gilead Sciences Inc | — | NEW | New buy |
| 11 | LLY | Eli Lilly & Co | — | NEW | New buy |
| 12 | IDYA | Ideaya Biosciences Inc | — | NEW | New buy |
| 13 | AVBP | Arrivent Biopharma Inc | — | NEW | New buy |
| 14 | PTCT | Ptc Therapeutics Inc | — | NEW | New buy |
| 15 | SNDX | Syndax Pharmaceuticals Inc | — | NEW | New buy |
| 16 | DXCM | Dexcom Inc | — | NEW | New buy |
| 17 | BBIO | Bridgebio Pharma Inc | — | NEW | New buy |
| 18 | REPL | Replimune Group Inc | — | NEW | New buy |
| 19 | RYTM | Rhythm Pharmaceuticals Inc | — | NEW | New buy |
| 20 | INSM | Insmed Inc | — | NEW | New buy |
| 21 | 2655787D | Blueprint Medicines CORP | — | NEW | New buy |
| 22 | BMY | Bristol-myers Squibb Co | — | NEW | New buy |
| 23 | INCY | Incyte CORP | — | NEW | New buy |
| 24 | ANAB | Anaptysbio Inc | — | NEW | New buy |
| 25 | SRPT | Sarepta Therapeutics Inc | — | NEW | New buy |
| 26 | AKRO | Akero Therapeutics Inc | — | NEW | New buy |
| 27 | AXSM | Axsome Therapeutics Inc | — | NEW | New buy |
| 28 | RAPP | Rapport Therapeutics Inc | — | NEW | New buy |
| 29 | SUPN | Supernus Pharmaceuticals Inc | — | NEW | New buy |
| 30 | SVRA | Savara Inc | — | NEW | New buy |
| 31 | EWTX | Edgewise Therapeutics Inc | — | NEW | New buy |
| 32 | COGT | Cogent Biosciences Inc | — | NEW | New buy |
| 33 | ROIV | Roivant Sciences Ltd. | — | NEW | New buy |
| 34 | DHR | Danaher CORP | — | NEW | New buy |
| 35 | PEN | Penumbra Inc | — | NEW | New buy |
| 36 | RNAGBP | Avidity Biosciences Inc | — | NEW | New buy |
| 37 | INBX | Inhibrx Biosciences Inc | — | NEW | New buy |
| 38 | YMABUSD | Y-mabs Therapeutics Inc | — | NEW | New buy |
| 39 | ✓ | — | NEW | New buy | |
| 40 | PHVS | Pharvaris N.V. | — | NEW | New buy |
| 41 | BIOA | Bioage Labs Inc | — | NEW | New buy |
| 42 | ACAD | Acadia Pharmaceuticals Inc | — | NEW | New buy |
| 43 | RCUS | Arcus Biosciences Inc | — | NEW | New buy |
| 44 | DYN | Dyne Therapeutics Inc | — | NEW | New buy |
| 45 | ✓ | Immatics NV | — | NEW | New buy |
| 46 | PRAX | Praxis Precision Medicines I | — | NEW | New buy |
| 47 | ISRG | Intuitive Surgical Inc | — | NEW | New buy |
| 48 | QURE | uniQure N.V. | — | NEW | New buy |
| 49 | IMNM | Immunome Inc | — | NEW | New buy |
| 50 | KURA | Kura Oncology Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Sofinnova Investments, Inc. reported a total U.S. public equity portfolio value of $1.9B across 62 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NTRA, SYK, QQQ) accounted for 28.7% of total reported equity market value during Q1 2025.
Top New Position Initiated
NTRA
市值: $219.2M
During Q1 2025, Sofinnova Investments, Inc.'s top holdings by market value included NTRA (14.3%)、SYK (7.3%)、QQQ (5.4%). The largest single position, NTRA, represented 14.3% of total portfolio value.
In Q1 2025, Sofinnova Investments, Inc. made 62 total portfolio adjustments, initiating 62 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.